![E3353_06 [ALT4ax].png](https://static.wixstatic.com/media/73af19_3c2aa92876234a68b46bead64acb0ce5~mv2.png/v1/crop/x_0,y_201,w_1987,h_1765/fill/w_947,h_841,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/E3353_06%20%5BALT4ax%5D.png)
Accelerate
the pathway to
clinical trials with
our revolutionary
machine learning
platform
Gain the
upper hand in
the evolutionary
arms race between
humans and pathogens
DEMYSTIFY
T CELL RECEPTORS
& UNLOCK A NEW
WORLD OF IMMUNE
THERAPIES
ABOUT
T Cell Receptors (TCRs) constitute one of the most promising classes of emerging therapeutics. Whilst TCRs are amongst the most complex facets of immune biology, engineering of an optimum T Cell Receptor can transform immunotherapies and personalised medicines.
Etcembly is building the world’s largest machine learning database and unmatched immunology expertise to deliver the safest and most powerful TCR immunotherapies through rapid computer-assisted engineering.
PEPTIDE
HEMISPHERE
SUCCESSFUL
IMMUNOTHERAPY RELIES
ON UNDERSTANDING
TWO HEMISPHERES
TCR
HEMISPHERE
APPROACHING THE CHALLENGE
The TCR repertoire at any time point reflects on the person’s health and contains a memory of all past experiences. However, TCRs are highly variable and their activities aren’t easily predictable with traditional empirical methods.
Data on a new TCR candidate should not only validate affinity, but also deliver exhaustive confirmation of every possibility of off-target, cross-reactive, or toxicity binding events.
By understanding an increasing database of TCR repertoires, Etcembly will be able to develop tools to assess immune health and identify disease biomarkers.
Our AI platform learns from the pattern of T cell target interactions and identifies T Cell Receptors that can be used to treat specific diseases in the clinic.
![E3353_06 [ALT4bxx].png](https://static.wixstatic.com/media/73af19_a0a2b607528d47b195ceef9aa79d5e05~mv2.png/v1/fill/w_1072,h_1084,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/E3353_06%20%5BALT4bxx%5D.png)
Etcembly has developed a proprietary machine learning platform - EMLy™ - trained and optimised to find deeply complex patterns in TCR repertoires. By leveraging this diversity, our AI, governed by biophysics, validated and optimised through empirical results, will lead to effective design of personalised therapeutics.
By employing our three-faceted TCR discovery platform, engineered to compress timelines and deliver rapid unbiased insights, your immune-based therapy will have the highest chance of success in specificity and efficacy in the quickest time possible.
INTRODUCING
Design
safe and potent
TCRs for the clinic
Optimise
TCR therapies
Create
diagnostics that identify the
right patient population
Determine
how the immune system is driven by external factors
such as ethnicity
and age
Design
personalised therapeutics
across all patient groups
THREE PILLARS TO SUCCESS
1: A well-trained, highly specific Machine Learning platform will explore the entire universe of possibilities, quickly identifying the highest potential TCR candidates that have the highest affinity and lowest probability of cross-reactivity, off-target or toxicity events.
2. Data-guided empirical optimisation cycles and engineering will rapidly develop ideal TCR candidate(s) and eliminate adverse effects.
3. Rigorous in vitro validation will provide the predictive confidence that the ideal TCR candidate is clinically safe and potent.
Data extraction on public domains
TCR OPTIMISATION
Neural networks
TCR candidates
Structural analysis of pHLA:TCR
Affinity measurement
Functional readout
Off-target
toxicity
DEEP NEURAL ARCHITECTURE
INTEGRATED WITH THE DATABASE
form the basis of EMLy’s computation in novel
diagnostic and theraputic solutions.
Deep sequencing
of patient derived
T cells (public domain and proprietry)
TCR Sequencing data (public domain and proprietry)
3D structural modelling
Profile biomarkers for treatment selection and outcome prediction
Novel and
optimised T cell and neoantigen-directed immunotherapies
Personalised immunotherapy design
BENEFITS
Aids
insurance
company
assessment
Helps
Healthcare
systems
Lean drug
discovery for pharma
Swift
pathway
to clinical
trials
![E3353_06 [ALT5d].png](https://static.wixstatic.com/media/73af19_6a36a6b3df964e3da401a538371ad188~mv2.png/v1/fill/w_980,h_908,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/73af19_6a36a6b3df964e3da401a538371ad188~mv2.png)
OUR TEAM
Michelle Teng
CEO Co-founder
20 years of R&D experience working on a breadth of projects from lead discovery to translational medicine.
Nick Pumphrey
CSO
Over 20 years' experience developing TCR-based therapeutics at Immunocore and Adaptimmune
Nick Cross
Chairman
Serial entrepreneur and investor.
Jacob Hurst
CTO Co-founder
25 years of bioinformatics experience spanning across translational medicine, HIV, TCR and antibody repertoire analytics
Scott Cuthill
CBO
Pharma veteran. Held senior BD roles at Chroma Therapeutics, Ipsen and ValoTx
Bent Jakobsen
Director
CEO of Accession Therapeutics
Founded Immunocore and Adaptimmune
Leon Toh
VP Operations (Asia Pacific)
Impact investment, founder of Damson Ventures
John McCafferty
Scientific Advisor
Serial entrepreneur. Founder of Cambridge Antibody Technology, Maxion Tx and IonTas
![E3353_06 [ALT5c].png](https://static.wixstatic.com/media/73af19_eb667bf734924150a00e411f0aa8ef5f~mv2.png/v1/fill/w_980,h_908,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/73af19_eb667bf734924150a00e411f0aa8ef5f~mv2.png)
PARTNERS
Contact
If you are as excited about our journey as
we are, then please drop us an email.
Careers
We are committed to developing the next generation of scientists and welcome motivated individuals who share our vision. If you aspire to break boundaries in precision medicine and are able to demonstrate understanding in the convergence of these fields, we are interested in hearing from you.
Get in touch here
